Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography

[1]  F. Mottaghy,et al.  Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival. , 2016, European journal of radiology.

[2]  Peter Hoskin,et al.  Squamous-cell carcinoma of the anus: progress in radiotherapy treatment , 2016, Nature Reviews Clinical Oncology.

[3]  M. Guren,et al.  Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. , 2015, European journal of cancer.

[4]  A. Kneebone,et al.  Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions. , 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

[5]  Johannes A Langendijk,et al.  Advances in Radiotherapy for Head and Neck Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Stanwell,et al.  Multiparametric MRI as an outcome predictor for anal canal cancer managed with chemoradiotherapy , 2015, BMC Cancer.

[7]  M. V. van Herk,et al.  Target delineation variability and corresponding margins of peripheral early stage NSCLC treated with stereotactic body radiotherapy. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  L. Thiberville,et al.  Areas of High 18F-FDG Uptake on Preradiotherapy PET/CT Identify Preferential Sites of Local Relapse After Chemoradiotherapy for Non–Small Cell Lung Cancer , 2015, The Journal of Nuclear Medicine.

[9]  V. Goh,et al.  Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  Jacqueline Esthappan,et al.  RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. , 2013, International journal of radiation oncology, biology, physics.

[11]  T. Wilsgaard,et al.  Impaired health-related quality of life after chemoradiotherapy for anal cancer: Late effects in a national cohort of 128 survivors , 2013, Acta oncologica.

[12]  Jan-Jakob Sonke,et al.  Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer , 2013, BMC Cancer.

[13]  A. Renehan,et al.  Current treatment of anal squamous cell carcinoma. , 2012, Hematology/oncology clinics of North America.

[14]  Trevor Leong,et al.  Clinical Investigation : Gastrointestinal Cancer Australasian Gastrointestinal Trials Group ( AGITG ) Contouring Atlas and Planning Guidelines for Intensity-Modulated Radiotherapy in Anal Cancer , 2012 .

[15]  Jan-Jakob Sonke,et al.  The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  M. Choti,et al.  Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  Philippe Lambin,et al.  FDG-PET-CT reduces the interobserver variability in rectal tumor delineation. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  M. V. van Herk,et al.  Repeat CT assessed CTV variation and PTV margins for short- and long-course pre-operative RT of rectal cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  M. Stock,et al.  Critical discussion of evaluation parameters for inter-observer variability in target definition for radiation therapy , 2012, Strahlentherapie und Onkologie.

[20]  Albert Siegbahn,et al.  Delineation of gross tumor volume (GTV) for radiation treatment planning of locally advanced rectal cancer using information from MRI or FDG-PET/CT: a prospective study. , 2011, International journal of radiation oncology, biology, physics.

[21]  T. Derlin,et al.  Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer. , 2011, International journal of radiation oncology, biology, physics.

[22]  M. Brambilla,et al.  FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma , 2010, Radiation oncology.

[23]  Frederik Maes,et al.  Biological image-guided radiotherapy in rectal cancer: challenges and pitfalls. , 2009, International journal of radiation oncology, biology, physics.

[24]  M. Krengli,et al.  (18)F-FDG-PET/TC Imaging for Staging and Radiotherapy Treatment Planning of Patients affected by Carcinoma of the Anal Canal , 2008 .

[25]  Tim Fox,et al.  PET-CT fusion in radiation management of patients with anorectal tumors. , 2007, International journal of radiation oncology, biology, physics.

[26]  T. Vuong,et al.  Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy. , 2007, International journal of radiation oncology, biology, physics.

[27]  Sanjiv S. Gambhir,et al.  Impact of Integrated PET/CT on Variability of Target Volume Delineation in Rectal Cancer , 2007, Technology in cancer research & treatment.

[28]  R. Ernst,et al.  Diagnosis and Diagnostic Imaging of Anal Canal Cancer. , 2017, Surgical oncology clinics of North America.

[29]  G. Hruby,et al.  The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer : A Systematic Review and Meta-analysis , 2015 .

[30]  N. Belnome,et al.  [Anal carcinoma]. , 2001, Annali italiani di chirurgia.